期刊
JOURNAL OF NEURAL TRANSMISSION
卷 126, 期 1, 页码 95-99出版社
SPRINGER WIEN
DOI: 10.1007/s00702-018-1879-z
关键词
Depression; Pharmacogenetics; Precision medicine; Antidepressant response; Randomized clinical trial; Baseline severity
Clinical utility of commercial multi-gene pharmacogenetic tests in depression is starting to be studied with some promising results on efficacy and tolerability. Among the next steps is the definition of the patient profile that is most likely to benefit from testing. Here we present a reanalysis of data from the AB-GEN randomized clinical trial showing that clinical utility of pharmacogenetic testing can be markedly influenced by patient characteristics such as age, baseline severity and duration of current depressive episode.Trial registration ClinicalTrials.gov NCT02529462.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据